- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patients With RRMM Are Undertreated With Carfilzomib in the Real World, Study Finds
Since carfilzomib was approved at a 27 mg/m2 twice-weekly dose, it has since been optimized at 56 mg/m2 twice-weekly and a recent study found benefits of a 70 mg/m2 once-weekly dose. However, most patients are still treated with the original approval dosage, suggesting they might be undertreated.
The majority of patients with relapsed/refractory multiple myeloma (RRMM) are being undertreated and are receiving carfilzomib (Kyprolis) at a lower dosage, according to research presented at the 60th American Society of Hematology Annual Meeting and Exposition.1
Since carfilzomib was approved in 2012 to treat RRMM, higher doses of the therapy have been studied. Since 2016, the dose has been optimized for patients to received 56 mg/m2 twice weekly (optimized dose-56 BIW) with dexamethasone, and the more recent A.R.R.O.W. study has shown that a once-weekly dose of 70 mg/m2 (70 QW) improves progression-free survival compared with the twice-weekly dose of 27 mg/m2 (27 BIW) that was approved.
Interim results of the phase 3 A.R.R.O.W. study were presented at the 2019 American Society of Clinical Oncology Annual Meeting and published in The Lancet Oncology.2
The authors used IQVIA’s Oncology Electronic Medical Records database to identify 1469 patients with MM who were diagnosed between January 1, 2010, and October 31, 2017, who received 3 or more doses of carfilzomib. They compared overall survival and time to next treatment (TTNT) among patients treated with 27 BIW with patients who received the optimized dose-56 BIW/70 QW.
Of the patients studied, 129 patients (8.8%) received either the optimized dose-56 BIW/70 QW and 1340 patients (91.2%) received 27 BIW. At 12 months, 90.3% of patients in the optimized dose-56 BIW/70 QW group were alive compared with 79.7% of patients in the 27 BIW group. Patients in the optimized dose-56 BIW/70 QW group also had a 64% lower risk of death than the 27 BIW group.
TTNT, which is a proxy for progression-free survival, was 17.5 months for the optimized dose-56 BIW/70 QW group, which was significantly longer than the 13.2 months for the 27 BIW group.
“Our findings suggest that these patient-relevant outcomes may be improved in a vast majority of RRMM patients currently under-treated with carfilzomib by optimizing the dose, taking into consideration patients’ comorbidities and ability to tolerate therapy,” the authors concluded.
References
- Medhekar R, Hines D, Panjabi S, Welliver T, Wang X, Wade RL. Could patients with multiple myeloma (MM) derive additional benefit from their treatments? Real-world evidence for carfilzomib dosing intensity on survival and treatment progression. Presented at the 60th American Society of Hematology Annual Meeting & Exposition; December 3, 2018. San Diego, CA. Abstract 836.
- Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
More than 5 years after the American Society of Clinical Oncology warned of emerging disparities in precision medicine, efforts by community practices to embrace technology, form partnerships, and use data show how patients can gain access to personalized approaches. But challenges remain, especially for those covered by Medicaid.
Read More
